Drug
Gamunex C
Gamunex C: highest development phase Phase 3, developed by Grifols. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Grifols
Trials
| Drug | Phase | Indication |
|---|---|---|
| Gamunex-C NCT07540221 | Phase 3 | CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) |
| Gamunex-C, 10% Injectable Solution NCT07582432 | Phase 3 | Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma |
| Gamunex-C NCT04450654 | Phase 2 | Immune-Mediated Necrotizing Myopathy |
| GAMUNEX-C NCT04480424 | Phase 2 | COVID-19 |
Latest
No recent events.
Follow Gamunex C on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.